3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
31
Advanced Solid Tumors
25
Advanced Solid Tumor
24
Carcinoma, Non-Small-Cell Lung
20
Neoplasms
15
Solid Tumor
12
Prostatic Neoplasms
12
Multiple Myeloma
12
Neoplasm Metastasis
11
Recurrence
10
Pancreatic Neoplasms
10
Small Cell Lung Carcinoma
9
Ovarian Neoplasms
9
Lung Neoplasms
9
Stomach Neoplasms
8
Melanoma
8
Lymphoma, Large B-Cell, Diffuse
8
Leukemia, Myeloid, Acute
8
Carcinoma, Hepatocellular
8
Triple Negative Breast Neoplasms
7
Sarcoma
7
Colorectal Neoplasms
7
Uterine Cervical Neoplasms
6
Solid Tumors
6
Carcinoma, Transitional Cell
5
Advanced Solid Tumour
5
Squamous Cell Carcinoma of Head and Neck
4
Nasopharyngeal Carcinoma
4
Myelodysplastic Syndromes
4
Lymphoma
4
Interventions
Fluorouracil
21
Oxaliplatin
17
Leucovorin
17
Bevacizumab
17
Irinotecan
13
Panitumumab
12
Cetuximab
12
IFL protocol
9
Capecitabine
9
pembrolizumab
7
Radiotherapy
7
Pemetrexed
5
Gemcitabine
5
labetuzumab
3
conatumumab
3
Cisplatin
3
Carboplatin
3
Albumin-Bound Paclitaxel
3
5,11-methenyltetrahydrohomofolate
3
130-nm albumin-bound paclitaxel
3
vatalanib
2
trametinib
2
spartalizumab
2
pegfilgrastim
2
ganitumab
2
encorafenib
2
dostarlimab
2
Ramucirumab
2
Paclitaxel
2
Melphalan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Rectal Neoplasms
×
Injections
×
Clear all
NCT07321847
2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3
Not yet recruiting
717 enrolled